Physician profile
Christine Saraceni
NPI 1659607844
$25,812.91
in general payments reported to CMS, 2019-2025
74 companies · $5,248 in 2025
The $5,248 reported for 2025 was more than what 83% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,455 · 2020: $1,555 · 2021: $4,127 · 2022: $3,696 · 2023: $3,901 · 2024: $4,831 · 2025: $5,248.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Consulting Fee: $2,480 · Long Term Medical Supply Or Device Loan: $1,250 · Education: $227.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,022.73 |
| Consulting Fee | $2,480.00 |
| Long Term Medical Supply Or Device Loan | $1,249.95 |
| Education | $227.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $3,471.91 | 2019-2025 | |
| Stemline Therapeutics INC. | $2,852.81 | 2023-2025 | Orserdu |
| Celgene Corporation | $1,245.16 | 2019-2025 | Reblozyl, Opdualag, Pomalyst |
| Janssen Biotech, INC. | $1,192.91 | 2019-2025 | Talvey, Darzalex, Tecvayli |
| Pfizer INC. | $1,162.96 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,145.72 | 2019-2025 | Opdivo, Opdualag |
| Genentech USA, INC. | $1,094.68 | 2019-2025 | Polivy, Alecensa, Rozlytrek |
| Astrazeneca Pharmaceuticals Lp | $991.66 | 2019-2025 | Lynparza, Imfinzi, Tagrisso |
| Amgen INC. | $944.76 | 2019-2023 | Nplate, Xgeva, Vectibix |
| Merck Sharp & Dohme LLC | $829.07 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Seagen INC. | $762.50 | 2019-2025 | Tukysa, Padcev |
| Abbvie INC. | $712.96 | 2021-2025 | Venclexta |
| Daiichi Sankyo INC. | $568.28 | 2019-2025 | Enhertu, Datroway, Injectafer |
| Lilly USA, LLC | $552.15 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Genzyme Corporation | $547.80 | 2019-2025 |
Show all 74 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $542.23 | 2020-2024 | Ultomiris |
| Rigel Pharmaceuticals, INC. | $462.33 | 2019-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Astellas Pharma US INC | $448.69 | 2019-2024 | Padcev, Xospata |
| Takeda Pharmaceuticals U.S.A., INC. | $404.65 | 2019-2025 | Fruzaqla, Ninlaro, Alunbrig |
| Pharmacyclics LLC, An Abbvie Company | $351.14 | 2020-2023 | Imbruvica, Epkinly |
| Puma Biotechnology, INC. | $348.93 | 2019-2024 | |
| Incyte Corporation | $329.07 | 2019-2025 | Jakafi, Niktimvo |
| Bayer Healthcare Pharmaceuticals INC. | $284.05 | 2019-2025 | |
| Array Biopharma INC | $283.40 | 2019-2025 | Braftovi, Mektovi, Lorbrena |
| Exelixis INC. | $281.35 | 2019-2025 | Cabometyx |
| Emd Serono, INC. | $258.03 | 2019-2023 | Tepmetko, Bavencio |
| Gilead Sciences, INC. | $252.91 | 2021-2025 | Trodelvy |
| Jazz Pharmaceuticals INC. | $245.11 | 2020-2024 | |
| Karyopharm Therapeutics INC. | $214.38 | 2020-2024 | Xpovio |
| Blueprint Medicines Corporation | $192.67 | 2020-2025 | Ayvakit |
| Regeneron Healthcare Solutions, INC. | $185.27 | 2021-2024 | Libtayo |
| Taiho Oncology, INC. | $170.64 | 2019-2025 | |
| Menarini Silicon Biosystems, INC. | $167.04 | 2024 | |
| Eisai INC. | $165.36 | 2019-2025 | |
| Mirati Therapeutics, INC. | $156.14 | 2023-2024 | Krazati |
| Ipsen Biopharmaceuticals, INC | $142.33 | 2021-2024 | Onivyde, Somatuline Depot, Tazverik |
| Glaxosmithkline, LLC. | $132.19 | 2023-2025 | Zejula, Shingrix, Jemperli |
| Aveo Pharmaceuticals, INC. | $118.07 | 2021-2024 | Fotivda |
| Genmab U.S., INC. | $107.46 | 2024-2025 | Tivdak |
| Adaptive Biotechnologies Corporation | $99.50 | 2023-2025 | Clonoseq |
| Kyowa Kirin, INC. | $85.64 | 2020-2023 | Poteligeo |
| Tersera Therapeutics LLC | $84.55 | 2021-2023 | Zoladex, Quzyttir |
| Sobi, INC | $82.15 | 2022-2025 | |
| Amag Pharmaceuticals, INC. | $79.31 | 2019-2021 | |
| Agios Pharmaceuticals, INC. | $79.30 | 2019-2024 | Pyrukynd |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.43 | 2019-2025 | |
| Morphosys, US INC. | $68.65 | 2021-2023 | Monjuvi |
| Clovis Oncology, INC. | $68.40 | 2019-2021 | |
| Myovant Sciences INC. | $66.13 | 2021-2022 | |
| Beigene USA, INC. | $62.31 | 2023-2025 | Brukinsa, Tevimbra |
| Kite Pharma, INC. | $57.08 | 2025 | Yescarta |
| Springworks Therapeutics, INC. | $48.06 | 2024 | Ogsiveo |
| Advanced Accelerator Applications | $47.10 | 2019-2020 | |
| G1 Therapeutics, INC. | $37.31 | 2022-2023 | Cosela |
| Sun Pharmaceutical Industries INC. | $36.10 | 2019-2020 | |
| Apellis Pharmaceuticals, INC. | $30.29 | 2023 | Empaveli |
| Verastem, INC. | $28.98 | 2020 | |
| Legend Biotech USA INC. | $28.86 | 2024 | |
| Geron Corporation | $27.65 | 2024 | Rytelo |
| Progenics Pharmaceuticals, INC. | $25.28 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $25.24 | 2019 | |
| Adc Therapeutics America, INC. | $24.51 | 2024 | |
| Dova Pharmaceuticals | $23.57 | 2021 | |
| Servier Pharmaceuticals LLC | $22.89 | 2025 | |
| Coherus Oncology, INC. | $21.89 | 2024 | |
| Deciphera Pharmaceuticals INC. | $21.69 | 2023 | Qinlock |
| Tolmar, INC. | $21.13 | 2023 | |
| Foundation Medicine, INC. | $20.40 | 2019 | |
| Pharmacosmos Therapeutics INC. | $19.97 | 2025 | Monoferric |
| Immunocore Limited | $18.26 | 2025 | Kimmtrak |
| Epizyme, INC. | $16.08 | 2021 | |
| Tolmar Pharmaceuticals, INC. | $15.41 | 2022 | |
| Beone Medicines USA, INC. | $14.36 | 2025 | Tevimbra |
| Acrotech Biopharma INC. | $13.66 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christine Saraceni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.